BASF Sweetens Evonik Bid to Over €11B: What the Revised Offer Means for European Chemicals Stocks

Event Analysis

As reported by Bloomberg and subsequently covered by Reuters on October 23, 2026, BASF SE has raised its indicative offer for Evonik Industries AG to approximately €24 per share, valuing the German specialty-chemicals group at more than €11 billion. Reuters noted it could not immediately verify the report, citing unnamed sources — meaning this remains an unconfirmed indicative bid, not a binding public offer. The revised proposal represents a meaningful step up from BASF's prior approach of roughly €22.15 per share (implying ~€10.3 billion), which Evonik reportedly rejected as insufficient to open formal talks or permit due diligence.

What makes this development significant is both the scale and the strategic framing. At over €11 billion, this would rank among the largest European industrial M&A transactions of the year, fitting squarely into the global acquisition and consolidation wave reshaping chemicals, materials, and industrial sectors. BASF CEO Markus Kamieth has reportedly sweetened non-price terms as well — pledging to honor Evonik's existing job guarantees through 2032 and offering production-site commitments — a concession that signals BASF is serious about clearing German labor and political hurdles that often stall domestic mega-deals.

The reported ~38% premium to Evonik's pre-announcement closing price is notable. It suggests BASF sees strategic value in Evonik's specialty-chemicals portfolio that the market had not been fully pricing in. This is also consistent with the broader cross-sector acquisition repricing dynamic, where acquirers in consolidating industries are increasingly willing to pay control premiums to secure scale and supply-chain positioning. However, completion is far from certain: BASF management has previously signaled it would not pursue a merger at any price, and competition authorities, financing conditions, and Evonik's board could all derail the process.

What This Means for Traders

The clearest near-term trade is Evonik equity, which surged as much as ~5.2% in Frankfurt following the Bloomberg report, per Seeking Alpha. The merger-arbitrage spread — the gap between Evonik's current market price and the reported €24 indicative bid — reflects a blend of execution risk, regulatory uncertainty, and the possibility BASF walks away. Traders playing acquisition-driven stock moves should note that an unconfirmed source-based report carries higher deal-break risk than a formal announcement; the spread is wide for a reason. For BASF, the market will weigh the financing burden and integration risk against the strategic rationale — acquirer stocks frequently face short-term pressure on large-premium deals.

Beyond the two principals, European specialty-chemicals peers could see modest re-rating if investors reassign control premiums across the sector — a classic M&A acquisition wave spillover. Any chemicals CFD or stock exposure in the European industrials space is worth monitoring for sympathy moves. Macro and crypto effects are expected to be negligible. CoinUnited's stock CFDs on both BASF and Evonik allow positioning outside Frankfurt exchange hours, which matters if further confirmation (or denial) emerges outside the European session.

Start Trading on CoinUnited.io

Create Your Free Account → — Trade crypto, stocks, forex, indices and commodities from one crypto-funded account. Leverage up to 2000x on selected products, subject to eligibility; fees are tiered by 30-day volume.